The increasing trend of carbapenem‐resistance (CR) and multi‐drug resistance (MDR) in A. baumannii worldwide has limited the therapeutic effectiveness of antibiotic therapy. The study was conducted to determine the prevalence of carbapenemases and integrons among the isolates of imipenem‐resistant A. baumannii (IRAB). A total of 71 non‐repetitive imipenem‐ resistant A. baumannii isolates were collected and tested for susceptibility to 17 antimicrobials. The modified Hodge test and EDTA‐disc synergy test were performed for the screening of carbapenemases and metallo‐β ‐lactamases (MBLs) production, respectively. Isolates were then subjected to multiplex‐PCR targeting genes encoding for OXA‐type carbapenemase, MBLs and integrases. Random amplified polymorphic DNA (RAPD) genotyping was performed to assess genetic relatedness. All isolates exhibited multi‐drug resistant phenotype. Colistin was the most active antimicrobial agent tested. Seventy‐one isolates (100%) demonstrated positive in the modified Hodge test. Thirty‐nine isolates showed positive in the EDTA‐disc synergy test, however, no MBL genes were detected. All strains possessed a blaOXA‐51‐like gene. The co‐exis‐tence of blaOXA‐51‐like/blaOXA‐23‐like/intI1, blaOXA‐51‐like/blaOXA‐23‐like, blaOXA‐51‐like/blaOXA‐24‐like was detected in 91.6% (n = 65), 5.6% (n = 4), 2.8% (n = 2), respectively. Analysis of the genetic con‐text of blaOXA‐23 showed the presence of ISAba1 upstream of blaOXA‐23. No ISAba1 was detected upstream of blaOXA‐51. Two different gene cassettes were found in these strains, and a high prevalence of aacA4, aadA1 and catB8 genes was observed. RAPD of 71 isolates showed 7 genotypes. The strains were mainly recovered from patients in intensive care unit, neurosurgery and department of respiratory disease. These findings show that multi‐drug resistance in A. baumannii is a common problem. This study also shows a high distribution of blaOXA‐23‐like and intI1 genes in imipenem‐resistant A. baumannii isolates. The clonal spread played an important role in the increase of OXA‐23 producing IRABs in the hospital environment. (© 2011 WILEY‐VCH Verlag GmbH Co. KGaA, Weinheim)
Subjects
- Agriculture (56)
- Anim Genet (13)
- Arrays (98)
- Barley (45)
- Beadchip (95)
- Bioinformatics (48)
- BMC Bioinformatics (7)
- BMC Genomics (43)
- Breeding (50)
- Cancer (15)
- Core facilities (26)
- Diabet Med (142)
- Diabetes (142)
- Diabetes (140)
- Diagnostics (1171)
- Events- courses, meetings (2)
- Fa Yi Xue Za Zhi (1)
- Fluidigm (32)
- Forensic Sci Int Genet (5)
- Genotyping (1172)
- Health (1143)
- Heredity (159)
- Hum Genet (9)
- Industry news (1123)
- J Anim Breed Genet (1)
- Lab Chip (48)
- Mapping (1147)
- Microbiology (7)
- Parasitology (6)
- Patents (6)
- Plant Methods (49)
- Population (37)
- Research – Animal (11)
- Research – Human (193)
- Research – Plants (56)
- Sequencing (1189)
- SNP Genotyping (1170)
- Taqman genotyping (46)
- Technology (26)
- Uncategorized (407)
- Wheat (45)
Pick-a-Key
Affymetrix
Agriculture
array genotyping
barley genotyping
bioinformatics
Cancer
diabetes genotyping
Diabetes mellitus type 2
DNA
DNA sequencing
fluidigm genotyping
Forensic Science
Gene
Gene expression
Genet Epidemiol
genetics
Genome
Genome-wide association study
genotyping
genotyping beadchip
Health
Human papillomavirus
Hum Immunol
Illumina
Methods Mol Biol
mutations
National Institutes of Health
parasitology
PCR
Pharmacogenet Genomics
Plant breeding
population
sequencing
SEQUENOM
Single-nucleotide polymorphism
SNP
snp array
snp arrays
snp barley
snp fluidigm
snp genotyping
taqman
Theor Appl Genet
typing diabetes
wheat genotyping
Contributors
Resources
- Chip-Seq Chip-Seq: Articles and protocols
- Custom gene synthesis Oligo and gene synthesis
- PCR Sequencing PCR Sequencing: Fresh news, techniques and articles
- RNAi delivery Articles and protocols on RNAi
Genotyping industry news
- T3D Licenses Drug Candidate from Dara Repositions It for Alzheimer's[…]
- The WIN Consortium in Personalized Cancer Medicine Welcomes the Blue Cross and Blue Shield Association as Its First Health Plan MemberThe Worldwide Innovative Networking WIN Consortium a leader in personalized cancer medicine today proudly announced that the Blue Cross and Blue Shield Association BCBSA an association of thirtyeight independent Blue Cross and Blue... […]
- Early Filings for Obamacare "Bronze Plans" Signal Higher OutofPocket Costs for ConsumersSUNNYVALE Calif. June 18 2013 PRNewswireUSNewswire A new analysis from HealthPocket Inc. of early health insurance rate filings finds that the least expensive plans under the Affordable Care Act ACA have higher outofpocket costs for consumers compared to... […]
- Bee and Pollinator Health a Serious Concern and a PriorityNEW YORK June 18 2013 PRNewswireiReach Across the globe people are celebrating Pollinator Week on June 1723 2013.&160; Established in 2007 Pollinator Week has grown exponentially in scope each year drawing the support and endorsement of governors mayo... […]
- Long Term Disability Claim Payments Increase While the Number of Covered Workers RisesPORTLAND Maine June 18 2013 PRNewswireUSNewswire &160;The Council for Disability Awareness CDA today released its eighth annual Long Term Disability Claims Review which consolidates and summarizes claim data and trends from America's top disability ins... […]
- Start Your Engines for Henry Ford Health System's Third Annual "Get Your Heart Racing" EventDETROIT June 18 2013 PRNewswire Henry Ford Health System and Ford Motor Company team up to deliver a car enthusiast dreamcometrue event September 13 &8211; 14 2013 Start with an exquisite Friday evening event at Eastern Market's recently revamped Shed... […]
- Lilly Declares ThirdQuarter 2013 DividendINDIANAPOLIS June 18 2013 PRNewswire The board of directors of Eli Lilly and Company NYSE LLY has declared a dividend for the third quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable September 10 2013 to shareholders o... […]
- Lilly's Zyprexa Under ScrutinyFederal regulators are investigating the death of two people who received an injection of an Eli Lilly antipsychotic drug. […]
- Lilly assumes development rights to potential type 2 diabetes drugEli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT401 from Canada's Transition Therapeutics who will receive a US $7 million milestone payment.The original 2010 agreeme... […]
- Repeated heartburn symptoms could be cancerPeople who treat and forget persistent heartburn using overthecounter remedies could be putting their lives at risk according to experts. […]